Melbourne, Feb 28, 2008 (ABN Newswire) - Further to Solagran Limited's (ASX: SLA) ASX announcement of 20 February 2008 in which it was stated that the award of Manufacturing Licences for both the prescription pharmaceutical Ropren and its active ingredient Bioeffective R was imminent, the Directors of Solagran are pleased to announce that the Ministry of Health of the Russian Federation has now issued these licences.

The Directors believe that based on the attached letter from the General Director of Galenopharm (Solagran’s manufacturing partner in St Petersburg), Ropren will be available for sale in Russia towards the end of April 2008 after it is officially released. This is now just an administrative formality. In the meantime, the company will officially advise the hospital networks in Moscow and St Petersburg of Ropren's impending availability.

As was announced on 18 July 2007 when Ropren was approved as a pharmaceutical and entered into the Russian Pharmacopoeia, supply constraints mean that distribution will initially be limited to Moscow and St Petersburg.

The company is currently working on a number of initiatives to put in place manufacturing capacity sufficient to meet the expected demand from both the remainder of Russia and the CIS countries.

The Directors would like to congratulate all members of the team involved in what has been a long and complex regulatory approval process. Special thanks are due to Mr Tamerlan Aslanbekovich Balaev of Galenopharm, for his tireless efforts throughout the entire regulatory approval process.